Onconetix, Inc. Price & Performance (ONCO)

Onconetix, formerly Blue Water Vaccines, is confronting a potential Nasdaq delisting due to its persistently low share price. Recent months have seen executive turnover, a reverse stock split, and ongoing merger negotiations with Ocuvex Therapeutics. The company aims to diversify beyond oncology, but uncertainty clouds its public market future.12

The biotech market has experienced heightened instability following sweeping job cuts at major U.S. health agencies, including the FDA and NIH. Investors cite policy changes and leadership shakeups as contributing to the sector’s uncertainty, with biotech stocks facing increased volatility and diminished hopes for a near-term rebound.34

Blue Water Vaccines, now Onconetix, has seen its stock price fluctuate sharply, with a significant drop over the past year despite attempted turnarounds. The company’s moves, including leadership changes and exploring new business directions, have yet to restore sustained investor confidence, as reflected in its ongoing market struggles.56